1. Home
  2. EAD vs IVVD Comparison

EAD vs IVVD Comparison

Compare EAD & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Income Opportunities Fund

EAD

Allspring Income Opportunities Fund

N/A

Current Price

$6.69

Market Cap

395.9M

Sector

Finance

ML Signal

N/A

Logo Invivyd Inc.

IVVD

Invivyd Inc.

N/A

Current Price

$1.90

Market Cap

437.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EAD
IVVD
Founded
2003
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
395.9M
437.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EAD
IVVD
Price
$6.69
$1.90
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.75
AVG Volume (30 Days)
141.5K
1.7M
Earning Date
01-01-0001
06-08-2026
Dividend Yield
8.91%
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
N/A
$143.48
Revenue Next Year
N/A
$25.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
110.47
52 Week Low
$5.89
$0.46
52 Week High
$7.18
$3.07

Technical Indicators

Market Signals
Indicator
EAD
IVVD
Relative Strength Index (RSI) 31.93 57.57
Support Level $6.68 $1.41
Resistance Level $6.93 $2.01
Average True Range (ATR) 0.05 0.11
MACD -0.02 0.05
Stochastic Oscillator 39.95 80.90

Price Performance

Historical Comparison
EAD
IVVD

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: